4/3
07:25 am
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "buy" rating re-affirmed by analysts at Citigroup Inc..
Medium
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "buy" rating re-affirmed by analysts at Citigroup Inc..
3/25
10:18 am
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $26.00 price target on the stock.
Low
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $26.00 price target on the stock.
3/25
08:17 am
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its price target raised by analysts at HC Wainwright from $15.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its price target raised by analysts at HC Wainwright from $15.00 to $16.00. They now have a "buy" rating on the stock.
3/25
08:17 am
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its price target lowered by analysts at Robert W. Baird from $13.00 to $10.00. They now have an "outperform" rating on the stock.
Low
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its price target lowered by analysts at Robert W. Baird from $13.00 to $10.00. They now have an "outperform" rating on the stock.
3/24
07:00 am
lrmr
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Medium
Report
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
3/3
04:05 pm
lrmr
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Medium
Report
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
1/29
08:15 am
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $18.00 price target on the stock.
Low
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $18.00 price target on the stock.
1/24
08:02 am
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
1/23
04:05 pm
lrmr
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
Low
Report
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia